Drugs / METHYLPYRROLIDONE
METHYLPYRROLIDONE
also known as
1-methylpyrrolidone · N-methyl pyrrolidinone · N-Methyl-2-pyrrolidone · N-methyl-pyrrolidone · NSC-4594
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02468687 | Aug 2015 → Oct 2021 | plasma cell myeloma | Peter MacCallum Cancer Centre, Australia | Completed | No outcome recorded |
Evidence & citations 9 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | METHYLPYRROLIDONE | ChEMBL registry synonym — accepted as the source's own label CHEMBL12543 ↗ |
| Known as | 1-methylpyrrolidone | ChEMBL registry synonym — accepted as the source's own label CHEMBL12543 ↗ |
| Known as | N-methyl pyrrolidinone | ChEMBL registry synonym — accepted as the source's own label CHEMBL12543 ↗ |
| Known as | N-Methyl-2-pyrrolidone | “N-Methyl-2-pyrrolidone (NMP) is a small molecule acetyl-lysine mimetic compound with potent (low micromolar range) immunomodulatory and direct anti-myeloma activity...” NCT02468687 ↗ |
| Known as | N-methyl-pyrrolidone | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02468687 ↗ |
| Known as | NSC-4594 | ChEMBL registry synonym — accepted as the source's own label CHEMBL12543 ↗ |
| Action | Inhibit | “BETbromodomain inhibition” NCT02468687 ↗ |
| Modality | Small molecule | “a small molecule acetyl-lysine mimetic compound” NCT02468687 ↗ |
| Route | Oral | “oral suspension” NCT02468687 ↗ |